Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/235437
Full metadata record
DC FieldValueLanguage
dc.contributor.CRUESPUNIVERSIDADE DE ESTADUAL DE CAMPINASpt_BR
dc.typeArtigo de periódicopt_BR
dc.titleChronic Obstructive Pulmonary Diseases In Children.pt_BR
dc.contributor.authorRibeiro, Jose Dirceupt_BR
dc.contributor.authorFischer, Gilberto Buenopt_BR
unicamp.authorJose Dirceu Ribeiro, Department of Pediatrics, Faculdade de Ciências Médicas (FCM), Universidade Estadual de Campinas (Unicamp), Campinas, SP, Brazil. Electronic address: jdirceuribeiro@gmail.com.pt_BR
unicamp.author.externalGilberto Bueno Fischer, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, RS, Brazil.pt
dc.subjectChildpt_BR
dc.subjectChronic Coughpt_BR
dc.subjectChronic Obstructive Pulmonary Diseasept_BR
dc.subjectCriançapt_BR
dc.subjectDoença Pulmonar Obstrutiva Crônicapt_BR
dc.subjectTosse Crônicapt_BR
dc.description.abstractTo verify and describe the main events related to the diagnosis and management of chronic obstructive pulmonary diseases in children (COPDC) and adolescents, considering the interrelated physiopathology, genetic, and environmental characteristics. Relevant literature from PubMed was selected and reviewed. COPDC have an environmental and/or genetic origin and its manifestation has manifold genotypes, phenotypes, and endotypes. Although COPDC has no cure, it can be clinically controlled. Chronic cough is the main symptom and bronchiectasis can be present in several COPDC patients. The management of COPDC is more effective if based on guidelines and when treatment regimen adherence is promoted. Oral and inhaled corticosteroids, bronchodilators, inhaled antibiotics, and treatment of pulmonary exacerbation (PE) are the bases of COPDC management, and should be individualized for each patient. Correct diagnosis and knowledge of risk factors and comorbidities are essential in COPDC management. Procedures and drugs used should be based on specific guidelines for each COPDC case. Treatment adherence is critical to obtain the benefits of management. COPDC clinical control must be evaluated by the decrease in PEs, improved quality of life, reduction of pulmonary function loss, and lung structural damage. For most cases of COPDC, monitoring by interdisciplinary teams in specialized reference centers with surveillance strategies and continuous care leads to better outcomes, which must be evaluated by decreasing pulmonary function damage and deterioration, better prognosis, better quality life, and increased life expectancy.en
dc.relation.ispartofJornal De Pediatriapt_BR
dc.relation.ispartofabbreviationJ Pediatr (Rio J)pt_BR
dc.identifier.citationJornal De Pediatria. v. 91, n. 6 Suppl 1, p. S11-25pt_BR
dc.language.isoengpt_BR
dc.description.volume91pt_BR
dc.description.firstpageS11-25pt_BR
dc.rightsfechadopt_BR
dc.sourcePubMedpt_BR
dc.identifier.issn1678-4782pt_BR
dc.identifier.doi10.1016/j.jped.2015.06.003pt_BR
dc.identifier.urlhttp://www.ncbi.nlm.nih.gov/pubmed/?term=26354868pt_BR
dc.date.available2016-05-23T19:41:03Z-
dc.date.accessioned2016-05-23T19:41:03Z-
dc.description.provenanceMade available in DSpace on 2016-05-23T19:41:03Z (GMT). No. of bitstreams: 1 pmed_26354868.pdf: 1146204 bytes, checksum: 17ae22adc770898db9052bc0e318a809 (MD5) Previous issue date: nullen
dc.identifier.urihttp://repositorio.unicamp.br/jspui/handle/REPOSIP/235437-
dc.identifier.idPubmed26354868pt_BR
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
pmed_26354868.pdf1.12 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.